Specify a stock or a cryptocurrency in the search bar to get a summary
Celcuity LLC
CELCCelcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Address: 16305?36th Avenue North, Minneapolis, MN, United States, 55446
Analytics
WallStreet Target Price
28.57 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CELC
Dividend Analytics CELC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CELC
Stock Valuation CELC
Financials CELC
Results | 2019 | Dynamics |